Latest Regulatory Filings News

Visionflex Group Limited reported a net cash outflow from operations for the December 2024 quarter but secured significant financing, extending its funding runway to nearly 15 quarters.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Top End Energy Limited reported a net cash outflow in its December quarter, reducing its cash reserves to $2.76 million and leaving funding for just over two and a half quarters. The company’s cash flow dynamics highlight the ongoing financial pressures typical in early-stage oil and gas exploration.

Latitude 66 Ltd posted a $1.75 million net cash outflow for the December quarter, ending with $2.18 million in cash reserves. The company anticipates lower costs ahead and intends to sell shares valued at around $850,000 to fund ongoing activities.

Bannerman Energy reported a substantial $14.17 million cash outflow in its December quarter, driven by aggressive exploration and evaluation investments, leaving the company with $81.1 million in cash reserves.

Stavely Minerals reported a $1.593 million net cash outflow for Q4 2024 but plans to reduce exploration expenditure in the coming quarter to preserve its $2.673 million cash balance.

Energy Action Limited reported a positive net cash inflow from operating activities of $1.076 million for the December quarter, maintaining a solid cash position amid ongoing financing arrangements.

New Murchison Gold Limited reports a significant 39% increase in indicated gold resources at its Crown Prince deposit and secures a strategic ore purchase deal with Westgold, setting the stage for mining to commence mid-2025.

E79 Gold Mines Limited reported a $169,000 net cash outflow from operating activities for the December 2024 quarter, maintaining a solid cash balance of $1.46 million as it continues its exploration efforts.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Waratah Minerals Limited reported a $2.01 million net cash outflow from operating activities in the December 2024 quarter, ending with $4.23 million in cash and equivalents. The company continues its exploration efforts but faces notable cash burn that may pressure future funding.